These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1717782)

  • 1. Antihypertensive effects of cilazapril, 2.5 and 5 mg, once daily versus placebo on ambulatory blood pressure following single- and repeat-dose administration.
    Lacourcière Y; Poirier L; Provencher P; Pyzyk M
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):219-23. PubMed ID: 1717782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of 2.5 and 5 mg cilazapril versus placebo on daily blood pressure load.
    Poirier L; Pyzyk M; Provencher P; Lacourcière Y
    Am J Hypertens; 1991 Nov; 4(11):913-5. PubMed ID: 1838693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen.
    Fernandez PG; Bolli P; Lee C
    Can J Cardiol; 1990 Mar; 6(2):53-8. PubMed ID: 2138051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding study of cilazapril (Inhibace) in patients with uncomplicated essential hypertension.
    Mroczek WJ; Klein J; Burris JF
    Clin Exp Hypertens A; 1991; 13(8):1415-32. PubMed ID: 1836986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients.
    Güntzel P; Kobrin I; Pasquier C; Zimlichman R; Viskoper JR
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):8-12. PubMed ID: 1708060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy.
    Lacourcière Y; Leenen F; Rangno R; Spence JD; Lenis JH; Myers MG
    Can J Cardiol; 1994; 10(6):605-10. PubMed ID: 8044721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure.
    White WB; McCabe EJ; Hager WD; Schulman P
    Clin Pharmacol Ther; 1988 Aug; 44(2):173-8. PubMed ID: 2969315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension.
    Kobrin I; Güntzel P; Viskoper R; Paran E; Zimlichman R
    Drugs; 1991; 41 Suppl 1():31-6. PubMed ID: 1712270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of cilazapril in elderly patients with essential hypertension. A multicenter study.
    Kobrin I; Ben-Ishay D; Bompani R; Dixon R; Hoverman RJ; Jones RW; Kögler P; Sanchez R
    Am J Med; 1989 Dec; 87(6B):33S-36S. PubMed ID: 2532458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive efficacy of cilazapril 2.5 and 5.0 mg once-daily versus placebo on office blood pressure and 24-hour blood pressure profile.
    Prager G; Klein P; Schmitt M; Prager R
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S93-9. PubMed ID: 7700076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of moderate salt restriction alone and in combination with cilazapril on office and ambulatory blood pressure.
    Uusitupa M; Korhonen M; Litmanen H; Niskanen L; Väisänen S; Rauramaa R
    J Hum Hypertens; 1996 May; 10(5):319-26. PubMed ID: 8817406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y; Asmar R
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilazapril: an overview of its efficacy and safety in hypertension.
    Szucs T; Schneeweiss A
    Cardiology; 1992; 80(1):34-41. PubMed ID: 1532534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effect of cilazapril in essential hypertensive patients. Clinical study with 24 h ambulatory blood pressure monitoring.
    Hiwatari M; Abe K; Yoshinaga K; Saito T
    Arzneimittelforschung; 1991 Nov; 41(11):1137-40. PubMed ID: 1839765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily trandolapril compared with the twice-daily formulation in the treatment of mild to moderate essential hypertension: assessment by conventional and ambulatory blood pressures.
    Poirier L; Bourgeois J; Lacourcière Y
    J Clin Pharmacol; 1993 Sep; 33(9):832-6. PubMed ID: 8227480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-four-hour ambulatory noninvasive continuous finger blood pressure measurement with PORTAPRES: a new tool in cardiovascular research.
    Schmidt TF; Wittenhaus J; Steinmetz TF; Piccolo P; Lüpsen H
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S117-45. PubMed ID: 1382159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators.
    Guthrie R; Reggi DR; Plesher MM; Saini RK; Battikha JP
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):306-11. PubMed ID: 8722432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of single and consecutive doses of cilazapril and its depressor effects in patients with essential hypertension.
    Shionoiri H; Gotoh E; Miyakawa T; Takasaki I; Oda H; Ueda S; Kaneko Y
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):269S-273S. PubMed ID: 2970854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.
    Ajayi AA; Elliott HL; Reid JL
    Br J Clin Pharmacol; 1986 Aug; 22(2):167-75. PubMed ID: 3019375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension.
    Belz GG; Breithaupt K; Erb K; Kleinbloesem CH; Wolf GK
    J Hypertens; 1989 Oct; 7(10):817-24. PubMed ID: 2531184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.